A Phase 1 interventional study of TNP-2092 capsules and Placebo in Helicobacter Pylori Infection, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.
Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study. The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic profile of TNP-2092 Capsules in asymptomatic healthy subjects with Helicobacter pylori infection, and to explore the preliminary efficacy of TNP-2092 Capsules in eradicating Helicobacter pylori.
This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study. The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic profile of TNP-2092 Capsules in asymptomatic healthy subjects with Helicobacter pylori infection, and to explore the preliminary efficacy of TNP-2092 Capsules in eradicating Helicobacter pylori.
In this study, three dose groups of 100 mg, 300 mg and 600 mg will be set up. The drug will be taken twice a day for 14 consecutive days, and last dose on the morning of Day 15. Fifteen subjects in each of the 100 mg and 300 mg dose groups will be randomized at a ratio of 4:1, with 12 subjects receiving the investigational product and 3 receiving placebo. Ten subjects in the 600 mg dose group will be randomized at a ratio of 4:1, with 8 subjects receiving the investigational product and 2 subjects receiving placebo.
TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15
Drug: TNP-2092 capsules
Subjects received TNP-2092 capsules orally twice daily at the dose of 300 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15
Drug: TNP-2092 capsules
Subjects received TNP-2092 capsules orally twice daily at the dose of 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15
Drug: TNP-2092 capsules
Subjects received TNP-2092 placebo capsules orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15
Drug: Placebo
Administration orally.
Also known as: Rifaquizinone capsules
Administration orally.
Also known as: TNP-2092 placebo capsules
Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs)
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Day 1 to Day 49
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Area Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Half Life (t1/2) of TNP-2092 on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Number of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose
Participants received 14 urea breath test \[14C UBT\] at 4 to 6 weeks after last dose.
Time frame: Four to 6 weeks after the last dose of the study drugs.
Accumulation Index Rac (AUC) of TNP-2092
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) is calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).
Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Accumulation Index Rac(Cmax) of TNP-2092
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) is calculated from the ratio of Cmax (Day 15) to Cmax (Day 1).
Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
| Milestone | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo |
|---|---|---|---|---|
| Started | 12 | 12 | 8 | 8 |
| Completed | 12 | 12 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| participants | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo |
|---|---|---|---|---|
| Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs) | 6 | 9 | 4 | 3 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1 | 62.8 ± 34.4 | 190 ± 86.5 | 618 ± 310 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1 | 17.7 ± 8.38 | 46.4 ± 21.7 | 149 ± 78.4 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1 | 4 ± 1 | 4 ± 1 | 4 ± 0.8 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 15 | 96.5 ± 46.5 | 274 ± 114 | 701 ± 274 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 15 | 93.3 ± 46.1 | 267 ± 112 | 692 ± 272 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 15 | 90.7 ± 41.1 | 250 ± 105 | 657 ± 257 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| µg/L | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 15 | 21.7 ± 9.35 | 59.9 ± 30.2 | 167 ± 75.6 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15 | 4 ± 0.9 | 3 ± 2 | 4 ± 0.5 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Half Life (t1/2) of TNP-2092 on Day 15 | 3.26 ± 1.29 | 7.3 ± 4.91 | 6.67 ± 2.57 |
Participants received 14 urea breath test \[14C UBT\] at 4 to 6 weeks after last dose.
| participants | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose | 1 | 1 | 0 | 1 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) is calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).
| ratio | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Accumulation Index Rac (AUC) of TNP-2092 | 1.65 ± 0.54 | 1.51 ± 0.99 | 1.19 ± 0.61 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) is calculated from the ratio of Cmax (Day 15) to Cmax (Day 1).
| ratio | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg |
|---|---|---|---|
| Accumulation Index Rac(Cmax) of TNP-2092 | 1.36 ± 0.46 | 1.61 ± 1.56 | 1.24 ± 0.66 |
Collected over Day 1 to Day 49. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNP-2092 Capsules 100 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| TNP-2092 Capsules 300 mg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| TNP-2092 Capsules 600 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Placebo | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 3/12 | 3/12 | 3/8 | 0/8 |
| Aspartate aminotransferase increasedInvestigations | 3/12 | 2/12 | 2/8 | 0/8 |
| Urinary tract infectionInfections and infestations | 1/12 | 2/12 | 1/8 | 0/8 |
| RashSkin and subcutaneous tissue disorders | 0/12 | 2/12 | 0/8 | 0/8 |
| Upper respiratory tract infectionInfections and infestations | 0/12 | 1/12 | 0/8 | 1/8 |
| White blood cell count increasedInvestigations | 1/12 | 0/12 | 0/8 | 1/8 |
| White blood cells urine positiveInvestigations | 0/12 | 0/12 | 1/8 | 0/8 |
| Blood albumin decreasedInvestigations | 0/12 | 0/12 | 0/8 | 1/8 |
| HeadacheNervous system disorders | 0/12 | 0/12 | 0/8 | 1/8 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/8 | 1/8 |
| Age, Categorical(Participants) | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 12 | 8 | 8 | 40 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.4 ± 7.99 | 32.7 ± 7.75 | 33.5 ± 5.78 | 34.0 ± 6.70 | 32.1 ± 7.24 |
| Sex: Female, Male(Participants) | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 4 | 2 | 13 |
| Male | 9 | 8 | 4 | 6 | 27 |
| Race (NIH/OMB)(Participants) | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 12 | 12 | 8 | 8 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Positive rates of carbon 14 urea breath test (14C UBT)(Participants) | TNP-2092 Capsules 100 mg | TNP-2092 Capsules 300 mg | TNP-2092 Capsules 600 mg | Placebo | Total |
|---|---|---|---|---|---|
| Count of participants | 12 | 12 | 8 | 8 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2016 to primary completion in Sep 2017, 10 months.
Results were first posted in Jan 2025, 7 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TNP-2092
TenNor Therapeutics (Suzhou) Limited